<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>DiosMetin 7-O-β-D-Glucuronide &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/diosmetin-7-o-%ce%b2-d-glucuronide/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 10:28:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>DiosMetin 7-O-β-D-Glucuronide &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>DiosMetin Targets INF2: New Colorectal Therapy</title>
		<link>https://bioengineer.org/diosmetin-targets-inf2-new-colorectal-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 02 Jun 2025 07:48:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Colorectal cancer therapy]]></category>
		<category><![CDATA[DiosMetin 7-O-β-D-Glucuronide]]></category>
		<category><![CDATA[INF2 biomarker]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<category><![CDATA[single-cell RNA sequencing]]></category>
		<guid isPermaLink="false">https://bioengineer.org/diosmetin-targets-inf2-new-colorectal-therapy/</guid>

					<description><![CDATA[Colorectal cancer (CRC) remains one of the most formidable challenges in oncology, ranking as the third most prevalent malignancy within the gastrointestinal tract and occupying the position of the second leading cause of cancer-related mortality worldwide. For decades, researchers have pursued the identification of molecular targets that could enable the development of efficacious, precision therapies. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">247853</post-id>	</item>
	</channel>
</rss>
